ICARE Newsletter Spring 2024

BRCA-Associated Prostate Cancer Treatment Updates

New studies to guide treatment strategies in men with prostate cancer and a BRCA mutation were recently published. Specifically, a recent study suggested that platinum-based chemotherapy may be as effective as PARP inhibitors for individuals with BRCA-positive metastatic castration-resistant prostate cancer.1 The study sheds light on treatment options for advanced prostate cancer patients. More recently, another another study of men with BRCA-associated metastatic castration-resistant prostate cancer treated with a PARP inhibitor (Olaparib) had improved survival regardless of whether the mutation was germline or somatic.2 This highlights the importance of tumor testing to help guide cancer treatment.

1Fazekas, et al. Eur Urol Oncol. 2023:S2588-9311(23)00174-8. PMID:37722977. Social media post Jan 3rd, 2024. Available at https://tinyurl.com/post1324;

2Mateo, et al. J Clin Oncol. 2024;42(5):571-583. PMID:37963304. Social media post Feb 20th, 2024. Available at https://tinyurl.com/post22024.

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-brca-associated-prostate-cancer-treatment-updates/